Differentiation of chronic lymphocytic leukemia b cells into immunoglobulin secreting cells decreases LEF-1 expression

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Gutierrez Jr , Albert ^a   Arendt, Bonnie K ^a   Tschumper, Renee C ^a   Kay, Neil E ^a   Zent, Clive S ^a   Jelinek, Diane F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN; INTERLEUKIN 15; INTERLEUKIN 2; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; TOLL LIKE RECEPTOR 9; WNT PROTEIN; CPG ODN 2006; CYTOKINE; IMMUNOGLOBULIN LIGHT CHAIN; OLIGODEOXYRIBONUCLEOTIDE; PRDM1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CANCER INHIBITION; CANCER STAGING; CELL STRUCTURE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN SECRETING CELL; LEUKEMIA CELL LINE; LIGHT CHAIN; MALE; MICROMORPHOLOGY; PHENOTYPIC VARIATION; PLASMA CELL; PRDM1 GENE; PROTEIN DEPLETION; PROTEIN EXPRESSION; SECRETORY CELL; SIGNAL TRANSDUCTION; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; CYTOPLASM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 80053585260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026056     Document Type: Article

References (34)

1. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194: 1625-1638.
2. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, et al. (2003) Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 1: 346-361.
3. Sherborne AL, Houlston RS, (2010) What are genome-wide association studies telling us about B-cell tumor development? Oncotarget 1: 367-372.
4. Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, et al. (2011) Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood 117: 1911-1916.
5. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, et al. (2010) LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 116: 2975-2983.
6. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, et al. (2010) Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12: 326-335.
7. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 101: 3118-3123.
8. Reya T, O'Riordan M, Okamura R, Devaney E, Willert K, et al. (2000) Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 13: 15-24.
9. Travis A, Amsterdam A, Belanger C, Grosschedl R, (1991) LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. Genes Dev 5: 880-894.
10. Nowak D, Stewart D, Koeffler HP, (2009) Differentiation therapy of leukemia: 3 decades of development. Blood 113: 3655-3665.
11. Vedantham S, Gamliel H, Golomb HM, (1992) Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res 52: 1056-1066.
12. Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR, (2011) Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 20: 361-372.
13. Meyer T, Stockfleth E, (2008) Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 17: 1051-1065.
14. Spaner DE, Masellis A, (2007) Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21: 53-60.
15. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, et al. (2010) Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 115: 5041-5052.
16. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, et al. (2007) The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21: 110-120.
17. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, et al. (2005) B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 11: 1490-1499.
18. Zupo S, Massara R, Dono M, Rossi E, Malavasi F, et al. (2000) Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 95: 1199-1206.
19. Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR, (1978) Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med 148: 1570-1578.
20. Cossman J, Neckers LM, Braziel RM, Trepel JB, Korsmeyer SJ, et al. (1984) In vitro enhancement of immunoglobulin gene expression in chronic lymphocytic leukemia. J Clin Invest 73: 587-592.
21. Totterman TH, Danersund A, Carlsson M, Nilsson K, (1987) Effects of recombinant interferon-alpha and-gamma on B-CLL cells in serum-free medium: expression of activation, differentiation, and CALLA antigens. Leukemia 1: 667-672.
22. Carlsson M, Matsson P, Rosen A, Sundstrom C, Totterman TH, et al. (1988) Phorbol ester and B cell-stimulatory factor synergize to induce B-chronic lymphocytic leukemia cells to simultaneous immunoglobulin secretion and DNA synthesis. Leukemia 2: 734-744.
23. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, et al. (2007) CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood 109: 1611-1619.
24. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, et al. (1996) Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 10: 866-876.
25. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, et al. (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95: 999-1006.
26. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C, (2006) Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 108: 3152-3160.
27. Put N, Konings P, Rack K, Jamar M, Van Roy N, et al. (2009) Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study. Genes Chromosomes Cancer 48: 843-853.
28. Darce JR, Arendt BK, Chang SK, Jelinek DF, (2007) Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J Immunol 178: 5612-5622.
29. Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, et al. (2006) LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 12: 1191-1197.
30. Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, et al. (2007) Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood 110: 2650-2658.
31. Schnaiter A, Stilgenbauer S, (2010) Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget 1: 472-482.
32. Puissant A, Robert G, Auberger P, (2010) Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 9: 3470-3478.
33. Wang B, Yu SC, Jiang JY, Porter GW, Zhao LT, et al. (2011) An inhibitor of arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells. Stem Cell Rev 7: 458-470.
34. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.